Anergis

About:

Anergis discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization.

Website: http://www.anergis.ch

Top Investors: BioMedPartners, Sunstone Life Science Ventures, BlueOcean Ventures, Esperante Ventures, VINCI CAPITAL

Description:

Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.